Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management across the European Union (PERFORM)
Aim
Description
The project also aims to differentiate between bacterial and viral infections by confirming the most accurate of them. A potential group of patients (primary, secondary and tertiary care) will be studied and a comprehensive fever management plan suitable for health care systems across the Europe will be developed
During the study, access to febrile patients will take place at phenotypic, transcryptomic (Genome and Proteome) and bioinformatics level that will characterize multi-national cohort of patients at a large-scale. In addition, study data of past large-scale multi-national studies will be used
Project lead partner
Imperial College of Science, Technology and Medicine (UK)
Partners
- London School of Hygiene and Tropical Medicine (LSHTM) (UK)
The University of Liverpool (LIV) (UK)
The Chancellor, Masters and Scholars of the University of Oxford (UOXF) (UK)
University of Newcastle Upon Tyne (UNEW) (UK)
Erasmus Universitair Medisch Centrum Rotterdam (EMC) (The Netherlands)
Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC) (The Netherlands)
Stichting Katholieke Universiteit (RUMC) (The Netherlands)
Ethniko kai Kapodistriako Panepistimio Athinon (NKUA) (Greece)
Servizo Galego De Saude (SERGAS) (Spain)
Medizinische Universitat Graz (MUG) (Austria)
Univerzitetni Klinicni Center Ljubljana (UKCL) (Slovenia)
Rīga Stradiņš University (Latvia)
Medical Research Council (MRC) (UK)
Micropathology Limited (MIC) (UK)
Biomerieux SA (France)
Ludwig-Maximilians-Universitaet Muenchen (LMU Muenchen) (Germany)
Universitaet Bern (UBERN) (Switzerland)
